The FDA is accelerating its review of Eli Lilly’s (LLY) experimental weight loss pill, reducing the internal evaluation period from 60 days to one week under a new fast-track pathway, Reuters’ Patrick Wingrove and Dan Levine reports. This follows Lilly’s push for a faster timeline, according to internal documents.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly & Co: Promising Future with Strong TRIUMPH-4 Trial Results and Strategic Pipeline Driving Growth
- Eli Lilly’s (LLY) Newest Weight-Loss Drug Delivers Strong Results in Late-Stage Trial
- Midday Fly By: Disney invests $1B in OpenAI, Oracle reports mixed Q2
- Video: Oracle drags on Nasdaq as report reignites AI spending concerns
- Morgan Stanley sees ‘minimal movement’ in Eli Lilly shares on retatrutide data